INTRODUCTION
============

Recent advances in genome-wide association studies (GWAS) and meta-analyses have identified 140 susceptibility loci for Crohn's disease (CD), an intestinal chronic inflammatory disease, in Caucasians;[@b1-gnl-09-767]--[@b4-gnl-09-767] however, the currently identified loci explain less than 30% of the heritable risk and account for relatively small increments in the risk of inflammatory bowel disease (IBD). Existing GWAS have focused on common variants (minor allele frequency \[MAF\] \>0.05), so strategies to enhance the identification of rare (MAF \<0.01) and low-frequency (MAF, 0.01 to 0.05) variants with increasing effect sizes are critical for the discovery of the remaining inherited factors.[@b5-gnl-09-767] Direct genotyping by targeted array, metabochip, immunochip using low-frequency variants, and genome sequencing are the methods currently available to investigate disease-causing rare variants linked to complex traits.[@b6-gnl-09-767] Genome seuquencing technologies have developed rapidly in recent years and this strategy can be used for a wide range of investigations, from monogenic Mendelian disorders to diseases with high degrees of genetic heterogeneity.

The human exome constitutes less than 5% of the genome, and whole exome sequencing (WES) studies can therefore be more cost effective than whole genome sequencing for focused research. In addition, protein-coding regions are more evolutionarily conserved and are more sensitive to genetic changes[@b7-gnl-09-767],[@b8-gnl-09-767] than nongenetic regions, making WES potentially more valuable for uncovering deleterious mutations. WES has been recently employed to circumvent the "diagnostic odyssey" by providing genetic diagnoses for hearing loss, muscular dystrophy, neuromuscular disease, retinitis pigmentosa, and mitochondrial disease. Mitochondrial disease was particularly notable because it was associated not only with mitochondrial genes, but also with hundreds of nuclear DNA genes.[@b9-gnl-09-767] Recently, a variety of primary immunodeficiencies (PIDs) and monogenic diseases were revealed to cause refractory infantile colitis.[@b10-gnl-09-767],[@b11-gnl-09-767] Therefore, WES is rapidly becoming a common clinical test for individuals with rare genetic disorders.[@b12-gnl-09-767],[@b13-gnl-09-767]

Despite these advances, the ability of WES models to uncover disease-causing variants associated with complex conditions, such as CD and type 2 diabetes, has not been established for all populations.[@b14-gnl-09-767],[@b15-gnl-09-767] Methods such as GWAS have been used to validate whether identified high-effect variants are common enough to be carried by large populations with CD. Rare and low-frequency variants may occur too infrequently to be identified as contributory for complex traits. In addition, genotypical and phenotypical differences exist between Caucasian and Asian populations with CD. For example, mutations within the nucleotide-binding-oligomerisation-domain (*NOD2/CARD15*) and autophagy-related 16-like 1 (*ATG16L1*) sequences were not associated with CD in Asian populations.[@b16-gnl-09-767]--[@b18-gnl-09-767] In addition, the prevalence of small bowel involvement and perianal fistula was higher in Asian patients than in Caucasian patients.[@b19-gnl-09-767],[@b20-gnl-09-767]

Herein, we used WES analysis of Korean children with CD with the aim of identifying rare variants associated with CD. Genetic susceptibility plays a more important role in the etiology of pediatric CD than adult CD, probably as a consequence of a higher burden of disease-causing mutations in affected children.[@b21-gnl-09-767] We therefore focused on patients with early-onset CD and severe symptoms such as more extensive disease at onset and rapid progression. In addition, we also asked whether genetic profiling of variants could assist in the medical decision-making process to determine optimal treatment of pediatric CD.

MATERIALS AND METHODS
=====================

1. Study population
-------------------

Twenty-two early-onset CD cases were diagnosed at the IBD Clinic of the Seoul Asan Medical Center. The basic characteristics and clinical phenotypes of the study subjects are summarized in [Table 1](#t1-gnl-09-767){ref-type="table"}. Among 230 CD children \<14 years of age, youngest children with severe phenotype were included. The severe phenotype was defined as Pediatric Crohn's Disease Activity Index scores were \>30 and simple endoscopic scores for CD were \>20 at the time of diagnosis. Independent DNA samples from unrelated individuals were collected and sequenced for use as reference exomes to allow evaluation of the burden of mutation in patient samples. Reference exomes were from controls with no history of gastrointestinal or autoimmune disease. Informed consent was obtained from the parents of all the patients and the study was approved by the local ethics committees.

2. Whole exome sequencing
-------------------------

The WES analysis pipeline involved quality checks, alignments, and annotation to identify nucleotides that differed between the patient and reference sequences.[@b22-gnl-09-767] Exome capture was performed using the Sure Select Human All Exon 38Mb kit (Agilent Technologies, Santa Clara, CA, USA). The captured, purified and amplified exome-targeting library from each patient was sequenced using an Illumina HiSeq2000 platform. Capture and sequencing were performed by Macrogen, Seoul, Korea. Paired-end sequences produced by HiSeq2000 were mapped to the University of California Santa Cruz human genome assembly hg19 (NCBI build 37.1) using the mapping program BWA (version 0.5.9rc1, <http://bio-bwa.sourceforge.net>). Picard tools (version 1.59, <http://picard.sourceforge.net/>) was used for removing PCR duplicates, SAMtools (version 0.1.18, <http://samtools.sourceforge.net>) was used for the creation of reads uniquely mapped to the reference genome, and BED tools (version 2.15.0, <http://bedtools.readthedocs.org>) was used to filter out reads that did not map to the targeted exonic regions. Variants were subsequently annotated using ANNOVAR (ver. November 2011, <http://www.openbioinformatics.org/annovar/>),[@b23-gnl-09-767] from file conversion to its input format, filtering with database of single nucleotide polymorphisms (dbSNPs) for the version of 135, and SNPs from the 1000 genomes (1000G) project (<http://genome.ucsc.edu/cgi-bin/hgLiftOver>). Candidate mutations were selected as those coding nonsynonymous, stop, and insertion/deletion (indels) variants that were present at an allele frequency of \<0.05 in the 1000G project database.

3. Panels of genes associated with IBD and PID
----------------------------------------------

To prioritize rare IBD-associated variants of potentially high impact, a comprehensive panel of known IBD-associated genes was selected from previous GWAS IBD data[@b1-gnl-09-767]--[@b4-gnl-09-767] and from our GWAS database for Korean-specific susceptibility genes (*ATG16L2*, *DUSP5*, and *TBC1D1*).[@b24-gnl-09-767],[@b25-gnl-09-767] The comprehensive list contained 267 IBD genes, and was used for cross-referencing with exome data from patients and controls ([Supplementary Table 1](#s1-gnl-09-767){ref-type="supplementary-material"}). One-fourth of very young IBD or IBD-mimic colitis cases are related to loss-of-function mutations in critical immune genes, and variants in known PID genes were therefore analyzed to exclude PID in patients with CD.[@b26-gnl-09-767] A comprehensive panel of 236 PID genes was assembled according to the 2014 report from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency and Monogenic IBD genes ([Supplementary Table 2](#s1-gnl-09-767){ref-type="supplementary-material"}).[@b10-gnl-09-767],[@b11-gnl-09-767] The specific variants in PID and monogenic IBD gene panels were classified according to the OMIM database (<http://omim.org>).

4. Prediction of potential functionality
----------------------------------------

Three *in silico* prediction algorithms were used to predict the effect of each amino acid change on protein function.[@b27-gnl-09-767]--[@b29-gnl-09-767] SIFT (sorts intolerant from tolerant substitutions) and/or PolyPhen2 (polymorphism phenotyping 2) ratings of "deleterious" indicated a predicted disease-causing effect. A Mutation-Taster prediction of "disease-causing" was subsequently used as a more detailed pathogenicity score. A higher PhyloP score was indicative of higher levels of evolutionary conservation.[@b30-gnl-09-767] In this study, highly conserved loci (PhyloP score ≥1.5) were considered to have potentially deleterious mutations if a rating of "deleterious" or "disease-causing" resulted from at least one of the three *in silico* prediction models.

RESULTS
=======

1. Exome sequencing
-------------------

Exome data were analyzed from 22 pediatric patients with CD and 18 reference individuals. Total read average was 78,473,095 bp. Seventy-eight percent of mappable reads were on-target reads and 86% of targeted bases were covered at 10× read depth. Each exome had, on average, 66,289 SNPs, with 20,196 found in exonic regions. Following a series of quality-control steps (SNP quality \>50, total read depth \>10, alternative read depth \>3), 171,898 variants were identified across the 40 exomes. Of those, we focused on 32,794 missense/nonsense/indel variants within exons. After 24,317 of these variants were removed due to their presence in the 18 control exomes, 8,477 unique variants from 5,625 genes were identified across 22 CD exomes.

2. Characteristics of coding variants in IBD-associated genes
-------------------------------------------------------------

Of the 8,477 unique variants from 5,625 genes, the 22 pro-bands carried 81 rare and low-frequency variants, of which MAF were less than 0.05 among 56 IBD-associated genes ([Supplementary Table 3](#s1-gnl-09-767){ref-type="supplementary-material"}). Two probands each carried nonsense mutations in *ATG16L1* and *NOD2*; however, these were not deleterious and were not highly conserved according to *in silico* prediction algorithms. With the exception of *ATG16L2* (rs11235604) and *TBC1D1* (rs117452860),[@b24-gnl-09-767] the remaining variants were of unknown significance (VUS), and their functional roles in mucosal immunity remain to be elucidated.

Among the 81 variants of the 56 IBD-associated genes, the most frequently occurring variants were carried by nine and four CD probands, and were found in *ATG16L2* (rs11235604) and *IL17REL* (rs142430606), respectively ([Table 2](#t2-gnl-09-767){ref-type="table"}). *ATG16L2*, a homolog of *ATG16L1*, was identified as a novel candidate gene for CD in a recent Korean GWAS.[@b24-gnl-09-767] *ATG16L1* functions in autophagy alongside *ATG5*.[@b31-gnl-09-767] In addition, *ATG16L1* is closely related to *NOD2*, which functions in an autophagy-mediated antibacterial pathway in CD.[@b32-gnl-09-767] However, little is known regarding the function of mutated *ATG16L2*. An additional SNP in *IL17REL*, rs142430606 (c.C785T; p.P262L), has not previously been associated with IBD and was not predicted to be deleterious through *in silico* prediction. Variant rs5771069 was previously associated with ulcerative colitis.[@b33-gnl-09-767] However, there is no linkage disequilibrium between rs5771069 and rs142430606. The association of *ATG16L2* and *IL17REL* with CD was confirmed using an internal CD GWAS database (n=533). The rs11235604 variant of *ATG16L2* was strongly associated with CD in a previous Korean GWAS (odds ratio \[OR\], 1.63; 95% confidence interval \[CI\], 1.27 to 2.10; imputed p-value=1.17×10^−4^) ([Supplementary Table 4](#s1-gnl-09-767){ref-type="supplementary-material"}).[@b24-gnl-09-767] The newly identified variant (rs142430606 in *IL17REL*) showed a marginal association with CD (OR, 2.04; 95% CI, 1.001 to 4.14; imputed p-value=4.53×10^−2^).

Twenty-four unique deleterious variants (10 low-frequency SNPs and 14 novel variants) in 21 genes were identified in the 22 probands ([Table 3](#t3-gnl-09-767){ref-type="table"}). The 10 low-frequency SNPs have not previously been reported as associated with IBD. All the variants were in evolutionarily conserved regions of IBD-associated genes; however, it remains to be determined whether heterozygous incidence is deleterious for these variants. No dose effects have previously been reported for these genes with respect to CD phenotypes.

3. Characteristics of coding variants in PID and monogenic IBD genes
--------------------------------------------------------------------

Using a PID and monogenic IBD gene panel, 35 variants in 24 PID genes were identified in the 22 probands and among the 35 variants, 10 variants in eight PID genes were predicted to be deleterious ([Table 4](#t4-gnl-09-767){ref-type="table"}); however, all the variants were VUS in the heterozygous state with the exception of *XIAP* (p.Q111X; XIAP deficiency), which were identified on the X chromosome of a male patient (proband 13). The XIAP protein plays an important role in activating the nuclear factor κB signaling pathway that leads to proinflammatory cascades.[@b34-gnl-09-767] The stopgain mutation (c.C331T; p.Q111X) in proband 13 was confirmed by Sanger sequencing ([Fig. 1](#f1-gnl-09-767){ref-type="fig"}) and was strongly indicative of XIAP deficiency. The mutation was located prior to the BIR2 and BIR3 domains, which play a role in the recruitment of RIP2 and apoptosis.[@b35-gnl-09-767] Proband 13 was diagnosed as having severe CD with perianal fistula at the age of 10 years. He presented reduced natural killer cell activity and recurrent episodes of bicytopenia with bacterial infections. A deleterious p.V561M variant in *CYBB*, of which can cause chronic granulomatous disease, was identified in proband 7. However, his respiratory burst tests were normal.

4. Correlation of patient profiles with deleterious variants
------------------------------------------------------------

Comorbidity of perianal issues in the 22 CD probands was related to the presence of a heterozygous variant (rs11235604) in *ATG16L2* (p\<0.002, chi-square test); however, proband 16, who was homozygous for the rs11235604 variant, did not suffer perianal problems. Probands 5 and 9 died of severe infantile IBD and perianal fistula at the age of 14 months and 8 years, respectively. These two probands carried a heterozygous variant of *IL10RA* (c.C301T; p.R101W), which was previously reported to be a causative gene for refractory infantile IBD when present in the homozygous state.[@b36-gnl-09-767] We therefore performed Sanger sequencing on *IL10RA* in the two probands and their healthy parents; however, no additional homozygote or compound heterozygote mutations in *IL10RA* were identified. In summary, no genotype-phenotype associations were noted in the probands with the exception of XIAP deficiency in proband 13.

DISCUSSION
==========

In this study, we performed WES analysis on samples from 22 children with CD, and identified 81 IBD-associated gene variants and 35 PID genes. One variant, rs11235604 in *ATG16L2*, was already identified as a CD susceptibility locus in our GWAS database.[@b24-gnl-09-767] A further variant, rs142430606 in *IL17REL*, was newly identified as a probable disease-causing rare variant. The GWAS dataset confirmed this variant to be marginally associated with CD (OR, 2.04; imputed p-value=4.53×10^−2^). PID genes were also examined, and a novel p.Q111X variant in *XIAP* was noted in a patient with CD. The majority of the rare variants, particularly 24 unique deleterious variants in conserved loci, were VUS. Further study is needed to determine the functional effects of these mutations. The identification of numerous VUS in the small study population suggests that WES might not yet be applicable to clinical decision making in the treatment of pediatric CD.

One possible explanation for the difficulties in interpreting interesting rare variants is that IBD-associated variants are too rare and genetically heterogeneous to allow statistically significant observation in a small population. Recent GWAS successfully found common disease-causing variants in populations with CD,[@b1-gnl-09-767]--[@b4-gnl-09-767] but those common variants accounted for less than 30% of the heritability of CD.[@b37-gnl-09-767] The majority of polymorphisms in the human genome are rare variants, but, due to the limited statistical power, the effects of rare variants on polygenic CD are not clear. Lack of information regarding gene function also hampers the interpretation of WES data. Approximately 5,000 genes are prioritized in databases such as OMIM, and functional interpretation of VUS not listed in the databases is difficult. This lack of functional information hampers the prioritization of candidate mutations for further analysis. Unlike diseases exhibiting Mendelian inheritance patterns that have clear genotype-phenotype correlations, complex diseases are affected by the regulatory variation of non-coding regions, cumulative effects of polygenic determinants, gene-gene interactions, gene-environment interactions, and epigenetic gene modification mechanisms, all of which present huge challenges for the study of complex traits. Due to this complexity, WES may not be sufficient to uncover critical determinants. For example, recent WES for complex traits such as type 2 diabetes and idiopathic epilepsy failed to identify any significant rare variants despite the use of large study populations.[@b14-gnl-09-767],[@b15-gnl-09-767]

The scope of our study was additionally limited by the challenges presented by WES analysis.[@b8-gnl-09-767],[@b38-gnl-09-767] First, WES involves applied computational genomics. Different sequencing methods produce sequences of varying length and depth and the results of "loss-of-function" predictions can vary with data formats and annotation software. In addition, detection of short sequence indels is limited to one third of the read length in WES. The very large amount of data required for WES analysis also poses a challenge in determining disease-causing mutations. Capturing specific genomic regions and the exome may reduce the complexity of the data and simplify the computational analysis. In the present study, the analysis was simplified by prioritizing IBD-associated genes from recent GWAS studies and genes of PID and monogenic IBD. Second, *in silico* prediction models show substantial disagreements.[@b39-gnl-09-767] In the present study, we used three programs to assess the deleterious extent of the identified mutations. SIFT predictions correlated with Polyphen-2 and Mutation-Taster predictions at levels of 40% to 67%. Care must be taken to avoid false hypotheses that primarily rely on current filtering parameters and variable interpretations of WES data.[@b38-gnl-09-767] Therefore, in addition to validation by Sanger sequencing, functional studies are important for the full assessment of deleterious variants; however, it is difficult to perform functional studies on the numerous variants presented in the current study. The identification of numerous VUS does not alleviate the "diagnostic odyssey" needed for some patients.

Nonetheless, based on the fact that IBD-mimicking colitis is frequently observed in immunodeficient infants, WES-based diagnosis for patients with monogenic IBD may be clinically practical.[@b26-gnl-09-767] The identification of mutations in *IL10RA* and *XIAP* by WES highlighted the need for hematopoietic stem cell transplantation in affected children.[@b40-gnl-09-767],[@b41-gnl-09-767] One-third of chronic granulomatous disease and one-fifth of XIAP-deficient patients develop a noninfectious chronic IBD similar to CD.[@b42-gnl-09-767],[@b43-gnl-09-767] Common variable immune deficiency, dyskeratosis congenita, immunodysregulation polyendocrinopathy enteropathy X-linked syndrome, and Wiskott-Aldrich syndrome are also frequently accompanied by infantile enterocolitis.[@b26-gnl-09-767] Using a panel of PID and monogenic IBD genes, our WES identified a novel *XIAP* variant carried by proband.[@b13-gnl-09-767] Detailed guidelines for the diagnosis of IBD using WES remain to be established.

In conclusion, although pediatric patients with severe phenotypes carried a wide spectrum of genetic susceptibility factors for CD, the numerous heterozygous VUS in IBD-associated genes remain to be functionally characterized. Subsequently, those VUS limit the practical clinical application of WES for CD patients and hamper any personalized application of our findings to individual CD patients; however, using WES, a Korean-specific variant in *ATG16L2* was found in CD patients with early-onset and severe phenotype, and a probable candidate variant in *IL17REL* was newly identified. In addition, WES in children may be beneficial for distinguishing CD secondary to PID, for example as a result of the loss of XIAP protein.
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###### 

Characteristics of Children with Crohn's Disease

  Proband no.   Age at diagnosis, yr   Symptom onset, yr   Sex   Family history   Paris classification   Evolution of disease phenotype   Biologics                                                                 
  ------------- ---------------------- ------------------- ----- ---------------- ---------------------- -------------------------------- ----------- ---- -------------------------------------------------------- -----------------
  Proband 1     9                      6                   F     No               L3→L2                  B1→B2B3                          P0          G1   Refractory colitis, colectomy                            IFX→HMR
  Proband 2     9.3                    8.7                 M     No               L3                     B1                               P0          G0   \-                                                       \-
  Proband 3     15.8                   12                  M     No               L1→L4b                 B1→B2B3                          P1          G1   Stricture, perforation                                   \-
  Proband 4     2.8                    2.3                 F     No               L3                     B1→B3                            P0          G0   Rectovaginal fistula                                     \-
  Proband 5     0.5                    0.3                 F     No               L2                     B1→B3                            P1          G1   Rectovaginal fistula, colostomy, severe colitis, death   IFX
  Proband 6     10.8                   9.4                 M     No               L3→L2                  B1→B2B3                          P0          G1   Severe colitis, ileostomy                                IFX→IFX+MTX
  Proband 7     13                     9.4                 M     No               L3→L4b                 B1→B3                            P0          G0   Recurrent surgeries                                      IFX
  Proband 8     9.9                    9.6                 F     No               L3                     B1                               P1          G0   \-                                                       IFX→HMR+MTX
  Proband 9     1.3                    0.8                 F     No               L2→L3                  B1→B2B3                          P0          G1   Refractory colitis, ileostomy, death                     IFX→HMR
  Proband 10    14.9                   14.2                M     Yes              L3                     B1                               P1          G0   Repeated perianal disease                                IFX
  Proband 11    11                     8.5                 M     No               L3                     B1                               P1          G0   Refractory colitis                                       IFX+AZA→HMR+MTX
  Proband 12    6.1                    5.4                 M     No               L1                     B1                               P1          G0   \-                                                       \-
  Proband 13    11                     8                   M     No               L2→L3                  B1→B3                            P0          G0   Refractory colitis, colectomy                            IFX→HMR
  Proband 14    13.1                   12.8                F     No               L3                     B1→B2B3                          P1          G0   Severe colitis                                           IFX→HMR
  Proband 15    12.6                   11.9                F     Yes              L3                     B3→B1                            P0          G0   Severe colitis, ileostomy                                IFX→HMR
  Proband 16    11.1                   10.8                F     Yes              L1                     B1                               P1          G0   Perianal abscess                                         IFX→IFX+MTX
  Proband 17    9.3                    8.8                 F     No               L1                     B1                               P0          G0   \-                                                       \-
  Proband 18    10                     9.5                 M     No               L3                     B1                               P1          G0   Repeated perianal disease                                IFX
  Proband 19    10.3                   9.7                 M     No               L3                     B1                               P1          G0   \-                                                       IFX→IFX+AZA
  Proband 20    10.8                   9.2                 M     No               L3                     B1                               P0          G0   \-                                                       IFX
  Proband 21    11.8                   11.1                M     No               L4b                    B1                               P0          G0   \-                                                       IFX
  Proband 22    9                      8                   M     No               L3→L4b                 B1→B2                            P0          G1   Repeated stricture and surgeries                         \-

L, location; B, behavior; P, perianal disease; G, growth; F, female; IFX, infliximab; HMR, adalimumab; M, male; MTX, methotrexate; AZA, azathiopurine.

###### 

Rare Variants in Inflammatory Bowel Disease-Associated Genes according to Frequency

  No. of case   SNP          *In silico* prediction Mutation                                                                                  
  ------------- ------------ --------------------------------- ---- ---- ------------- ------------- -------- -------- --- ------ --- --- --- -------
  9             *ATG16L2*    11                                6    Ns   72,533,536    rs11235604    C658T    R220W    O   0.03   D   B   N   1.38
  4             *IL17REL*    22                                11   Ns   50,436,488    rs142430606   C785T    P262L    .   0.01   T   B   N   −0.21
  3             *HLA-DRB5*   6                                 2    Ns   32,489,856    rs77853982    G196A    D66N     O   .      T   .   P   0.61
  2             *IL10RA*     11                                3    Ns   117,860,269   .             C301T    R101W    .   .      D   D   D   2.46
  2             *IL10RA*     11                                6    Ns   117,866,312   rs41354146    G697A    V233M    .   0.01   T   D   N   0.67
  2             *TBC1D1*     4                                 11   Ns   38,053,599    rs117452860   C1990T   P664S    .   0.01   T   P   D   2.66
  2             *IFIH1*      2                                 10   Ns   163,134,021   .             G1948A   D650N    .   .      T   B   N   0.72
  2             *IL31RA*     5                                 13   Ns   55,204,174    rs140524514   G1379A   S460N    .   0      T   B   N   −0.23
  2             *MANBA*      4                                 16   Ns   103,556,114   rs142248415   T2246A   L749H    .   0      D   D   D   0.849
  2             *MLH3*       14                                5    Ns   75,506,696    rs28757011    G3488A   G1163D   .   0.01   T   B   D   1.44
  2             *MST1*       3                                 14   Ns   49,722,469    .             C1598G   T533S    .   .      T   B   .   2.63
  2             *NOS2*       17                                19   Ns   26,093,543    rs28944173    A2239G   T747A    .   0.01   T   B   N   1.94
  2             *SLC11A1*    2                                 14   Ns   219,259,458   rs142636978   G1492A   G498S    .   0.01   T   B   N   −0.54

SNP, single nucleotide polymorphism; UCSC, university of California Santa Cruz; SIFT, sorts intolerant from tolerant substitutions (D, damaging with low confidence or damaging; T, tolerated); Ns, nonsynonymous; Polyphen-2, polymorphism phenotyping 2 (B, benign; D, probably damaging; P, possibly damaging); Mutation Taster (N, not disease-causing; P, possibly disease-causing; D, disease-causing).

###### 

Deleterious Rare Variants in Inflammatory Bowel Disease-Associated Genes

              SNP   Genotype in each proband   *In silico* prediction                                                                                                                                                                                      
  ----------- ----- -------------------------- ------------------------ ------------- ------------- -------- -------- --- ------ ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- --- --- --- -------
  *ADAD1*     4     8                          Ns                       123,332,475   .             T893A    L298H    .   .      \-   \-   \-   \-   \-   1    \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   D   D   D   2.193
  *CREB5*     7     4                          Ns                       28,610,098    .             C308T    P103L    .   .      \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   1    \-   \-   \-   \-   \-   \-   D   D   D   2.583
  *CXCR2*     2     3                          Ns                       219,000,272   .             A748C    M250L    .   .      \-   \-   \-   \-   1    \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   .   D   N   2.045
  *DUSP5*     10                               Ns                       112,262,500   .             C401T    S134L    .          \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   1    \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   D   D   D   2.85
  *FAM55A*    11    5                          Ns                       114,393,621   .             A662G    Y221C    .   .      \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   1    T   D   N   2.031
                                                                                                                                                                                                                                                           
  *FAM55A*    11    6                          Ns                       114,392,694   rs79916924    G1214T   C405F    .   0      \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   1    \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   D   D   N   2.511
  *HNF4A*     20    4                          Ns                       43,042,364    rs1800961     C350T    T117I    O   0.02   \-   \-   \-   \-   \-   \-   \-   \-   \-   1    \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   T   B   D   2.388
                                                                                                                                                                                                                                                           
  *IFIH1*     2     6                          Ns                       163,138,942   .             G1240C   A414P    .   0      \-   \-   \-   \-   1    \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   T   D   D   2.822
                                                                                                                                                                                                                                                           
  *IL10RA*    11    3                          Ns                       117,860,269   .             C301T    R101W    .   .      \-   \-   \-   \-   1    \-   \-   \-   1    \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   D   D   D   2.461
  *LRRK2*     12    32                         Ns                       40,707,861    rs33958906    C4624T   P1542S   O   0.02   \-   \-   1    \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   T   D   D   2.753
                                                                                                                                                                                                                                                           
  *MST1*      3     4                          Ns                       49,724,902    .             G365A    R122Q    .   .      \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   1    \-   \-   \-   \-   \-   \-   T   D   D   2.547
                                                                                                                                                                                                                                                           
  *NOS2*      17    19                         Ns                       26,093,543    rs28944173    A2239G   T747A    .   0.01   \-   \-   1    \-   \-   \-   \-   \-   \-   \-   \-   \-   1    \-   \-   \-   \-   \-   \-   \-   \-   \-   D   B   N   1.941
  *PLCL1*     2     2                          Ns                       198,948,882   rs150675435   G641T    W214L    .   0      \-   1    \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   .   D   .   2.836
                                                                                                                                                                                                                                                           
  *RFTN2*     2     1                          Ns                       198,540,106   .             C77T     P26L     .   .      \-   \-   \-   \-   \-   1    \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   D   D   D   2.747
  *SH2B1*     16    1                          Ns                       28,878,223    .             C808T    R270W    .   .      \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   1    \-   \-   \-   \-   \-   \-   \-   \-   \-   D   D   N   2.06
  *SLC11A1*   2     3                          Ns                       219,248,982   .             G167A    R56Q     .   .      \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   1    \-   \-   \-   \-   \-   D   P   D   2.62
  *SULT1A1*   16    4                          Ns                       28,619,655    .             C329T    P110L    .   .      \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   1    \-   \-   \-   \-   \-   \-   \-   D   D   D   1.566
  *SULT1A2*   16    2                          Ns                       28,607,104    .             G148A    G50S     .   .      \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   1    .   D   D   2.148
  *SULT1A2*   16    7                          Stopgain                 28,603,710    rs138147609   G649T    E217X    .   0.01   \-   \-   \-   \-   1    \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   D   .   D   2.3
                                                                                                                                                                                                                                                           
  *TAB1*      22    5                          Ns                       39,813,741    rs145235801   C437T    P146L    .   0      \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   1    \-   \-   \-   \-   \-   \-   \-   \-   T   B   D   2.659
  *TBC1D1*    4     11                         Ns                       38,053,599    rs117452860   C1990T   P664S    .   0.01   \-   \-   \-   1    \-   \-   \-   \-   \-   \-   1    \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   T   P   D   2.664
  *THADA*     2     20                         Ns                       43,776,463    rs143275203   C2992G   R998G    .   0      \-   \-   \-   \-   1    \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   T   D   D   2.753
                                                                                                                                                                                                                                                           
  *TNFSF18*   1     1                          Ns                       173,020,010   .             G93A     M31I     .   .      \-   \-   \-   \-   1    \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   D   B   N   2.76
                                                                                                                                                                                                                                                           
  *ZMIZ1*     10    24                         Ns                       81,070,858    rs149174704   G3013A   D1005N   .   0      \-   \-   \-   \-   \-   1    \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   D   D   D   2.327

Novel variants are shown in gray.

1, heterozygote; 2, homozygote; SNP, single nucleotide polymorphism; UCSC, university of California Santa Cruz; SIFT, sorts intolerant from tolerant substitutions (D, damaging with low confidence or damaging; T, tolerated); Ns, nonsynonymous; Polyphen-2, polymorphism phenotyping 2 (B, benign; D, probably damaging; P, possibly damaging); Mutation Taster (N, not disease-causing; D, disease-causing).

###### 

Deleterious Rare Variants in Genes of Primary Immune Deficiency and Monogenic Inflammatory Bowel Disease

             SNP   Genotype in each proband   *In silico* prediction                                                                                                                                                                           
  ---------- ----- -------------------------- ------------------------ ------------- ------------- -------- -------- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- --- --- --- -------
  *BLM*      AR    15                         Ns                       91,328,232    .             C2744T   A915V    \-   \-   \-   \-   \-   1    \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   T   P   D   2.775
  *CYBB*     XL    X                          Ns                       37,670,138    .             G1681A   V561M    \-   \-   \-   \-   \-   \-   2    \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   .   D   D   2.31
  *DOCK8*    AR    9                          Ns                       328,113       rs75352090    C782T    A261V    \-   \-   \-   \-   \-   \-   \-   \-   \-   1    \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   T   D   D   2.798
  *DOCK8*    AR    9                          Stop gain                463,655       rs79568455    C5907A   Y1969X   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   1    \-   \-   \-   \-   \-   T   .   D   2.508
  *FOXN1*    AR    17                         Ns                       26,851,668    .             T271G    F91V     \-   \-   \-   \-   \-   \-   \-   \-   1    \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   D   D   N   2.174
  *IL10RA*   AR    11                         Ns                       117,860,269   .             C301T    R101W    \-   \-   \-   \-   1    \-   \-   \-   1    \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   D   D   D   2.461
  *NCF2*     AR    1                          Ns                       183,556,112   .             G175A    A59T     \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   1    \-   \-   D   P   D   2.562
  *NCF2*     AR    1                          Ns                       183,536,358   rs13306581    C836T    T279M    \-   \-   1    \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   D   D   D   2.535
  *RAG1*     AR    11                         Ns                       36,595,188    rs146457887   C334T    R112C    \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   1    \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   D   D   D   2.937
  *XIAP*     XL    X                          Stop gain                123,019,843   .             C331T    Q111X    \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   \-   1    \-   \-   \-   \-   \-   \-   \-   \-   \-   D   .   D   1.7

1, heterozygote; 2, homozygote; SNP, single nucleotide polymorphism; SIFT, sorts intolerant from tolerant substitutions (D, damaging with low confidence or damaging; T, tolerated); Polyphen-2, polymorphism phenotyping 2 (D, probably damaging; P, possibly damaging); Mutation Taster (N, not disease-causing; D, disease-causing); Ns, nonsynonymous; AR, autosomal recessive; XL, X-linked.
